Page 227 - Abstract Book KONIKA 18

Hemato-Oncology

P-HO-003
A 5-year-old Girl with Stage 4 Malignant Melanoma

Aldila Vidya Ditha Arianti, Ariawan, Bambang Sudarmanto
Department of Child Health, Faculty of Medicine, Universitas Diponegoro, Semarang, Central Java, Indonesia

Abstract
Background Malignant melanoma (MM) is an uncommon type of childhood cancer. The incidence is
approximately 1 of 1,000,000. Childhood melanoma is considered more prevalent in certain groups,
such as patients with giant congenital nevi and xeroderma pigmentosum. The 5-year survivals were 14%.
Objective We report on a case of stage IV malignant melanoma to address the clinical features of this disease
and the treatment using dacarbazine (DTIC). Case A 5-year-old girl admitted due to the presence of malignant
melanoma involving the dorsal, forehead, arm and legs. Biopsy in 2017 revealed a giant congenital nevi. The
lesion was larger than 50 cm, observed in mostly the dorsal part of the body, which was partially covered
by hair with irregular pigmentation. Biopsy in 2021 revealed a malignant melanoma. This year, the clinical
features showed a development of lymph nodes enlargement at the axilla and inguinal, > 1 cm diameter,
darkened lesion accompanied by pain in both of his extremities which made her unable to walk. So far,
this was the first case of MM who managed to received 2 cycles of DTIC. Conclusion We should have an
awareness of melanoma in children that have giant congenital nevi.
Keywords: malignant melanoma; treatment; dacarbazine; children

P-HO-004
Effect of Deferiprone and Deferasirox in Alleviation of Oxidative Stress
and Hyperuricemia in Beta Thalassemia Major Pediatric Patients

1
Andreas Budi Wijaya , Wulandewi Marhaeni , Wivina Riza Devi 2
1
2
Department of Pediatrics and Department of Clinical Pathology , Ulin General Hospital, Faculty of Medicine,
1
Universitas Lambung Mangkurat, Banjarmasin, South Borneo, Indonesia
Abstract
Background Oxidative stress in β-TM patients is associated with increased malondialdehyde (MDA)
level and decreased superoxide dismutase (SOD) level. Hyperuricemia, which was noted in 58% of β-TM
pediatric patients in Ulin Hospital, might be associated with body's response to reduce oxidative stress.
Deferiprone and deferasirox, which used for iron overload treatment, suggest the potential of antioxidants
Objective To evaluate the effect of deferiprone and deferasirox on oxidative stress parameter and uric acid
serum in β-TM pediatric patients. Methods Eighty seven β-TM patients (aged 2-≤18 years old) with iron
chelators (deferiprone or deferasirox) and regular transfusion in Ulin Hospital between April-July 2019,
were enrolled into this cohort study. They were followed up for 3 months. The laboratory investigations
included complete blood count, ferritin, uric acid, MDA and SOD. Statistical analysis was used to compare
ferritin, uric acid, MDA, and SOD before and after 3 months use of consecutive iron chelators agent.
Results Subjects (n=87) from this study were 61% male and 39% female. Deferiprone was used by 74.7%
patients. After being followed for 3 months, mean ferritin level of deferiprone group [3272.2 (SD 294.1)
ng/mL] was significantly lower (P=0.018) than that of deferasirox group [4926.1 (SD 803.2) ng/mL). There
was no significant difference in MDA, SOD and uric acid level between two groups. In comparison to
baseline data, there was significant increase in SOD level (P=0.000) and decrease in uric acid (P=0.000),
MDA (P=0.000) and ferritin level (P=0.000). Conclusion: Deferiprone and deferasirox can protect against
oxidative stress and hyperuricemia in β-TM pediatric patients
Keywords: deferiprone; deferasirox; oxidative stress; hyperuricemia; thalassemia

KONIKA XVIII Abstract Book 179